**Low GI (Glycemic Index) rice** is a premium, health-focused alternative to traditional white rice, specifically developed to support blood sugar management. Unlike standard varieties that cause rapid glucose spikes, this rice features a low glycemic index, meaning it is digested and absorbed at a much slower, more stable rate.

It provides sustained, long-lasting energy, helps curb sudden hunger cravings, and supports healthy weight management. This makes it an exceptional dietary choice for individuals managing diabetes, tracking fitness goals, or simply pursuing a balanced lifestyle. Best of all, it retains the familiar, fluffy texture and delicious taste of everyday rice.

An **Ampullary Biopsy** is a specialized diagnostic procedure performed to evaluate abnormalities in the ampulla of Vater—the crucial junction where the bile and pancreatic ducts empty into the small intestine. Utilizing Endoscopic Retrograde Cholangiopancreatography (ERCP) or standard endoscopy, a gastroenterologist visualizes the area and extracts small tissue samples.

This precise diagnostic test is critical for differentiating between benign conditions, such as inflammatory tissue or adenomas, and malignant tumors like ampullary carcinoma. By providing definitive histopathological analysis, an ampullary biopsy guides clinicians in formulating accurate, timely treatment plans and ensuring targeted patient care.

An **Amputation (Limb) Biopsy** is a critical diagnostic procedure performed to analyze tissue from a severely diseased, non-viable, or previously amputated limb. Unlike standard small-needle biopsies, this intervention involves sampling bone, muscle, or vascular structures from a major limb segment.

Pathologists utilize this diagnostic test to investigate aggressive underlying conditions, such as primary bone malignancies (like osteosarcoma), deep soft-tissue sarcomas, or severe, necrotizing infections. By providing definitive histological confirmation of a disease's type and margin involvement, the biopsy plays a crucial role in establishing accurate post-surgical diagnoses and tailoring subsequent oncological or medical treatments.

An **Amylase Diagnostic Test** is a routine blood or urine analysis used to measure the levels of amylase, an enzyme primarily produced by the pancreas and salivary glands to help digest carbohydrates. This test is most frequently ordered to evaluate, diagnose, or monitor acute or chronic pancreatitis, a condition characterized by painful inflammation of the pancreas.

Rapidly elevated amylase levels in the bloodstream often signal pancreatic injury, blockages in the pancreatic duct, or other gastrointestinal disorders. By providing quick, reliable metrics, this test serves as a foundational tool for clinicians establishing timely interventions and managing abdominal emergencies.

An **Amylase Enzymatic Ascitic Fluid Diagnostic Test** analyzes the fluid accumulated within the abdominal cavity—known as ascitic fluid—to measure the concentration of the digestive enzyme amylase. This specialized evaluation is crucial when clinicians suspect that a patient’s ascites is driven by pancreatic pathology rather than liver disease.

Markedly elevated amylase levels in the fluid typically signify a pancreatic duct disruption, severe acute pancreatitis, or a pancreatic pseudocyst leaking into the peritoneum. By differentiating pancreatic ascites from other causes, this diagnostic test provides vital clarity, enabling medical teams to deliver highly targeted, urgent therapeutic interventions.

An **ANA Blot Diagnostic Test** (Antinuclear Antibody Blot) is an advanced blood analysis used to identify specific autoantibodies targeting a patient's own cellular nuclei. Unlike a standard ANA screen that simply confirms the presence of antibodies, this immunoblotting technique identifies the exact target proteins, such as Smith (Sm), RNP, SSA, SSB, or Scl-70.

This precise diagnostic tool is vital for diagnosing, differentiating, and monitoring complex systemic autoimmune disorders. It provides critical laboratory data that helps clinicians definitively distinguish between conditions like Systemic Lupus Erythematosus (SLE), Sjögren's syndrome, scleroderma, and mixed connective tissue disease to guide targeted treatment.

An **ANA Profile Diagnostic Test** is a comprehensive blood panel ordered following a positive Antinuclear Antibody (ANA) screen to investigate systemic autoimmune disorders. While a standard screen merely indicates the presence of autoantibodies, the profile identifies and measures specific antibodies, including anti-dsDNA, anti-Smith, anti-SSA, anti-SSB, and anti-RNP.

This detailed diagnostic panel is vital for clinicians to differentiate between complex connective tissue diseases such as Systemic Lupus Erythematosus (SLE), Sjögren's syndrome, mixed connective tissue disease, and scleroderma. By mapping a patient's unique autoantibody blueprint, it confirms precise diagnoses and guides tailored treatment strategies.

An **ANA Screening by IFA Diagnostic Test** (Antinuclear Antibody Screening by Immunofluorescence Assay) is the gold-standard blood test used to detect autoantibodies that mistakenly target a patient's own cellular nuclei. Utilizing a fluorescent microscope, laboratory technicians examine human epithelial cells (HeP-2) mixed with the patient's blood serum to look for specific glowing patterns.

This critical diagnostic screening is the foundational first step in identifying systemic autoimmune conditions, such as Systemic Lupus Erythematosus (SLE), Sjögren's syndrome, and rheumatoid arthritis. A positive result provides crucial initial data, prompting further specific autoantibody testing to establish an accurate medical diagnosis.